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Coadministration of Atorvastatin Prevents
Nitroglycerin-Induced Endothelial Dysfunction
and Nitrate Tolerance in Healthy Humans
Andrew Liuni, BSC,*† Mary Clare Luca, BSC,*† Giuseppe Di Stolfo, MD,‡ Amar Uxa, MD,*
Justin A. Mariani, MD, PHD,* Tommaso Gori, MD, PHD,§ John D. Parker, MD*†
Toronto, Ontario, Canada; Siena, Italy; and Mainz, Germany
Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of toler-
ance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans.
Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase in-
hibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant
mechanism.
Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and pla-
cebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin
(80 mg/day), all for 7 days. On the second visit, forearm blood flow was measured with venous-occlusion strain
gauge plethysmography in response to incremental infusions of acetylcholine (7.5, 15, and 30 g/min). Acetyl-
choline infusions were coinfused first with saline, and repeated during the coinfusion of vitamin C (24 mg/min).
Blood pressure responses to sublingual GTN (400 g) were assessed on both visits.
Results Acetylcholine responses in the GTN plus placebo group were significantly attenuated versus those in the GTN
plus atorvastatin and atorvastatin groups (p  0.01). Coinfusion of vitamin C completely restored acetylcholine
responses in the GTN plus placebo group (p  0.01 vs. saline coinfusion), but caused no change in either the
atorvastatin or the GTN plus atorvastatin groups. Blood pressure responses to sublingual GTN did not signifi-
cantly change between visits in subjects receiving GTN plus atorvastatin and atorvastatin alone, but were signifi-
cantly blunted in the GTN plus placebo group (p  0.05).
Conclusions The present findings demonstrate, for the first time in humans, that atorvastatin prevents both GTN-induced en-
dothelial dysfunction and nitrate tolerance, likely by counteracting the GTN-induced increase in oxidative
stress. (J Am Coll Cardiol 2011;57:93–8) © 2011 by the American College of Cardiology Foundation















ritroglycerin (GTN) and other organic nitrates are widely
sed in the management of cardiovascular disease. The
ascular effects of GTN are mediated by the release of nitric
xide (NO) or an NO-related species by denitrification of
he nitrate ester (1). However, the clinical utility of chronic
TN therapy is limited by the rapid loss of the hemody-
amic and anti-ischemic effects, a phenomenon termed
olerance (2). Both experimental and clinical observations
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ther authors have reported that they have no relationships to disclose.(
Manuscript received March 29, 2010; revised manuscript received July 6, 2010,
ccepted July 13, 2010.ndicate that an important cause of nitrate tolerance is an
ncrease in the vascular bioavailability of reactive oxygen
pecies (ROS) (3). Multiple sources of ROS have been
escribed in response to nitrate therapy, including nicotin-
mide adenine dinucleotide phosphate oxidases, mitochon-
ria, and uncoupled NO synthase (NOS) (1). The increased
ioavailability of ROS also results in the development of
ndothelial dysfunction, a consequence of sustained nitrate
herapy that is now well documented (4–6). These obser-
ations have led to a number of new concepts concerning
he etiology of tolerance, the role of nitrate biotransforma-
ion as a trigger of increased free radical production, as well
s the exploration of multiple therapeutic strategies to
revent the nitrate-induced increase in ROS (7,8). Recent
bservations in animal models have demonstrated that concur-
ent therapy with 3-hydroxy-3-methylglutaryl coenzyme A
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dysfunction associated with chronic
GTN therapy by directly counter-
acting the GTN-induced increase
in ROS (9–11). Whether HMG-
CoA reductase inhibitor administra-
tion can preserve GTN responsive-
ness and prevent the development
of GTN-induced endothelial dys-
function in humans, and whether a
similar antioxidant mechanism is
involved, has yet to be established.
Methods
The Mount Sinai Research Ethics
Board approved this investigator-
initiated, non–industry-funded
study, and all subjects gave writ-
en informed consent before beginning the study. Studies
ere conducted in a quiet, temperature- and humidity-
ontrolled environment.
tudy population. Thirty-six normal healthy, male, non-
moking volunteers (18 to 27 years of age) were enrolled in
randomized, parallel trial. All subjects were required to
ast and abstain from caffeine for 14 hours before the study.
xclusion criteria included any active disease, the use of
edications (including supplemental vitamins), as well as
isk factors for cardiovascular disease such as hypertension,
moking, a family history of premature cardiovascular dis-
ase, and hypercholesterolemia as defined by Canadian
uidelines (12).
tudy visit 1. After admission into the study, standing
lood pressure and heart rate were measured using an
utomatic, calibrated sphygmomanometer (GE Healthcare,
ississauga, Ontario, Canada). Baseline forearm blood flow
FBF) then was measured by forearm venous-occlusion
train gauge plethysmography, as described previously (4,6).
fter these measurements were complete, subjects were
dministered 400 g GTN as a sublingual spray, and
eat-to-beat blood pressure was monitored from the middle
nger of the dominant hand using a finometer system
Finapres Medical Systems, Amsterdam, the Netherlands)
or the next 4 min. Thirty minutes later, subjects were
andomized to receive transdermal GTN 0.6 mg/h and
torvastatin (80 mg/day), transdermal GTN 0.6 mg/h and
atching placebo, or atorvastatin alone. Repeat standing
lood pressure and heart rate measurements were obtained
h later. At the conclusion of visit 1, subjects were given a
-day supply of either atorvastatin or placebo and were
nstructed to take 1 pill daily at 9 AM until the end of the
tudy. Subjects assigned to GTN treatment were given a
upply of transdermal GTN 0.6 mg/h for the following 6
ays. Subjects were instructed to wear the patch continu-





ANOVA  analysis of
variance




NO  nitric oxide
NOS  nitric oxide
synthase
ROS  reactive oxygen
species
SBP  systolic blood
pressureedications (placebo and atorvastatin) were administered in pdouble-blind fashion, whereas GTN patches were admin-
stered in an investigator-blinded fashion (in this case study,
ersonnel not involved in data acquisition or analysis were
esponsible for randomization procedures and answering
ny questions subjects had during the study).
tudy visit 2. After 7 days of study medication, subjects
eturned to the laboratory for the assessment of: 1) resis-
ance artery endothelial function and tolerance; and 2) the
ole of oxidative stress in GTN- and atorvastatin-induced
hanges in endothelial responses. Standing blood pressure
nd heart rate measurements were repeated as described in
isit 1. After being completed, the brachial artery of the
ondominant arm was cannulated as previously described
4). The FBF then was measured during intra-arterial
nfusions of normal saline and in response to increasing
oncentrations of the endothelium-dependent vasodilator
cetylcholine chloride (ACh), as described previously (4,6).
Ch was first coinfused with normal saline; ACh responses
ubsequently were repeated with a vitamin C coinfusion (24
g/min) (6). When FBF measurements were complete and
lood flow values had returned to baseline, subjects were
dministered 400 g GTN as a sublingual spray and
eat-to-beat blood pressure from the middle finger of the
ominant hand was measured as described for visit 1.
tatistical analysis. All results are expressed as mean 
D. All FBF values are presented as the ratio of the infused
ersus the noninfused arm (4,8). This approach normalizes
he results obtained over time because of small alterations in
ympathetic activation, blood pressure, or both (13) and is
onsidered more repeatable and reliable than absolute values
f FBF in the infused arm alone (14). Normality was
ssessed for all variables in each of the 3 groups using the
hapiro-Wilk test. Several of the variables were not nor-
ally distributed; the data were transformed using the
atural log, which yielded normal distribution. Within- and
etween-group differences were evaluated with a repeated-
easures analysis of variance (ANOVA). A doubly
epeated-measures ANOVA was used to assess the differ-
nces in FBF between groups, the effect over time (coinfu-
ions), as well as the group by time interaction. A value of
 0.05 was set as the threshold for significance. SAS
oftware (version 9.2, SAS Institute Inc., Cary, North
arolina) was used for all statistical analyses.
esults
eart rate and blood pressure responses. Results of heart
ate and blood pressure responses are summarized in Table 1.
aseline standing heart rate and systolic blood pressure
SBP) did not differ significantly between the groups on visit
. Heart rate increased significantly 3 h after the first dose
f transdermal GTN in the GTN plus placebo and GTN
lus atorvastatin groups, and it remained significantly
igher on visit 2 in the GTN plus atorvastatin group. After
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December 28, 2010/January 4, 2011:93–8 Nitroglycerin and Endothelial Functionhe first transdermal preparation, standing systolic blood
ressure was significantly lower in the GTN plus placebo
nd GTN plus atorvastatin groups. On visit 2, SBP returned
o baseline values in the GTN plus placebo group. In
ontrast, standing SBP in the GTN plus atorvastatin group
emained lower when compared with baseline. There were
o significant differences in blood pressure or heart rate at
ny time point in the atorvastatin group. Blood pressure and
eart rate did not change significantly in response to any of
he intra-arterial drug infusions.
lood pressure responses to sublingual GTN adminis-
ration. On visit 1, SBP responses to a single sublingual
ose of 400 g GTN were similar between groups (11 
mm Hg, 9  3 mm Hg, and 10  4 mm Hg for the
TN plus placebo, GTN plus atorvastatin, and atorvastatin
lone groups, respectively; p  NS). On visit 2, SBP
esponses remained similar in the GTN plus atorvastatin
nd atorvastatin alone groups and did not differ significantly
rom the values obtained on visit 1 (9  3 mm Hg and
9  4 mm Hg for the GTN plus atorvastatin and
torvastatin groups, respectively; p  NS). In contrast, the
eduction in SBP with sublingual GTN was significantly
lunted in the GTN plus placebo group (5  3 mm Hg,
 0.001 vs. visit 1, p  0.05 vs. GTN plus atorvastatin
nd atorvastatin groups) (Fig. 1).
BF responses. On visit 1, FBF was similar between the 3
roups (data not shown). On visit 2, when coinfused with
aline, a dose-dependent increase in FBF in response to
ach infused concentration of ACh was observed in all
roups. However, FBF responses were blunted significantly
n the GTN plus placebo group compared with the GTN
lus atorvastatin and the atorvastatin alone groups (p 
.01, for the effect of group) (Table 2) (Fig. 2). When
oinfused with vitamin C, ACh responses in the GTN plus
lacebo group were restored compared with saline confusion
p  0.01, for the interaction of time and group) and did
ot differ significantly from those in the GTN plus atorva-
tatin and atorvastatin groups (p  NS, for the effect of
lood Pressure and Heart Rateespons to Transdermal GTNTable 1 Blood Pr ssure and Heart RateResponses to Transdermal GTN
Visit 1
Visit 2Baseline 3 h after GTN
Systolic blood pressure (mm Hg)
GTN  placebo 117 10 104 7* 118 6
GTN  atorvastatin 116 10 103 8† 109 7‡
Atorvastatin 117 10 117 10 118 12
Heart rate (beats/min)
GTN  placebo 79 12 100 15* 81 13
GTN  atorvastatin 78 12 94 12† 85 14‡
Atorvastatin 74 12 77 13 79 11
p  0.001 versus baseline and visit 2. †p  0.01 versus baseline and visit 2. ‡p  0.05 versus
aseline.
GTN  nitroglycerin.roup) (Table 2) (Fig. 3). Vitamin C did not alter ACh-nduced responses in the GTN plus atorvastatin or the
torvastatin alone groups.
hanges in lipid profiles. The changes in lipid profiles are
ummarized in Table 3. After 7 days of atorvastatin admin-
stration, significant decreases were observed in total cho-
esterol levels and low-density lipoprotein cholesterol in the
TN plus atorvastatin and atorvastatin groups. There were
o significant differences in lipid profiles between visits in
he GTN plus placebo group, nor were there any significant
etween-group differences.
iscussion
he present study demonstrates, for the first time in
umans, the ability of the HMG-CoA reductase inhibitor
torvastatin to prevent the development of tolerance and
ndothelial dysfunction associated with sustained GTN
herapy in normal volunteers, an effect mediated, at least in
art, by a reduction of oxidative stress in the vasculature.
Continuous treatment with GTN and other organic
itrates is associated with a loss of clinical efficacy and the
evelopment of important abnormalities in endothelial
unction. The mechanism behind these phenomena seems
o be multifactorial, including impaired biotransformation
f GTN by mitochondrial aldehyde dehydrogenase and
ossible neurohumoral activation (15). Furthermore, a large
ody of work points to the generation of ROS during
ustained GTN therapy, initially from mitochondrial and
ventually cytosolic sources, as a central component to this
athophysiology (16). Although the interactions of ROS are
ultiple, an important target is endothelium-derived NO,
eading to the formation of peroxynitrite. Peroxynitrite can
xidize tetrahydrobiopterin, uncoupling the NOS enzyme
nd reducing endothelial NO bioavailability. In support of
hese hypotheses, previous reports have confirmed that
herapy with GTN is associated with the development of
ignificant endothelial dysfunction and NOS uncoupling in
Figure 1 Blood Pressure Responses to
Sublingual GTN Administration
Bar graph showing systolic blood pressure (SBP) responses to a single sublin-
gual dose of 400 g GTN expressed as the change in SBP from baseline. After
chronic therapy with GTN, responses were significantly blunted in the GTN plus
placebo group but were preserved in the GTN plus atorvastatin group and in
the atorvastatin alone group. Data are mean  SEM. *p  0.001 for within-
group comparison versus visit 1. †p  0.05 for between-group comparison ver-
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n effect that can be prevented by the coadministration of
ntioxidants (6).
The HMG-CoA reductase inhibitors have become stan-
ard therapy in patients with hypercholesterolemia and
oronary artery disease and are effective in the primary and
econdary prevention of cardiovascular events (17–19).
t is now clear that the benefits associated with the
MG-CoA reductase inhibitors extend beyond choles-
erol reduction and that these drugs possess cholesterol-
ndependent, or pleiotropic, effects (20). Such effects
nclude antioxidant, anti-inflammatory, antithrombotic,
s well as vascular-protective properties, possibly medi-
ted by an increase in NO bioavailability. The HMG-
oA reductase inhibitors have been hypothesized to
ncrease NO bioavailability through multiple mecha-
isms. These include a direct increase in NOS enzymatic
ctivity, through phosphatidylinositol-3-kinase/protein
inase Akt-mediated phosphorylation; increased produc-
ion of its essential cofactor tetrahydrobiopterin; and an
Figure 2 FBF Responses to ACh Coinfused With Saline
Bar graph showing responses to incremental intra-arterial infusions of acetyl-
choline chloride (Ach) (7.5, 15, and 30 g/min) coinfused with normal saline
in the 3 groups. The FBF is expressed as the ratio of infused to noninfused
arm. The forearm blood flow (FBF) responses were significantly blunted in the
nitroglycerin (GTN) plus placebo group (p  0.01, for the effect of group). Data
are mean  SEM. Statistical analysis was performed after natural log transfor-
mation. NS  normal saline.
FBF ResponsesTable 2 FBF Responses
GTN  Placebo
Saline/saline 1.1 0.2 (0.1 0.2)
Saline/ACh (7.5 g/min) 1.3 0.5 (0.2 0.4)
Saline/ACh (15 g/min) 2.2 1.3 (0.7 0.6)
Saline/ACh (30 g/min) 2.7 1.3 (0.9 0.5)
Vitamin C/saline 1.0 0.1 (0.0 0.1)
Vitamin C/ACh (7.5 g/min) 2.9 1.3 (1.0 0.4)
Vitamin C/ACh (15 g/min) 4.3 1.8 (1.4 0.4)
Vitamin C/ACh (30 g/min) 6.1 2.9 (1.7 0.5)
Values are expressed as the ratio of the infused to the noninfused arm
of group. †p  0.01, for the interaction of time and group.
ACh  acetylcholine chloride; FBF  forearm blood flow; ln  natuncrease in NOS messenger ribonucleic acid half-life
20,21). Collectively, these pleiotropic effects may act both
o improve and preserve vascular function in response to a
umber of risk factors or exposures that are associated with
he development of endothelial dysfunction and atheroscle-
osis. Because treatment with organic nitrates, particularly
TN, is associated with the development of endothelial
ysfunction, it has been hypothesized that HMG-CoA
eductase inhibitors could modify the vascular responses to
ustained nitrate therapy. This hypothesis was tested in 3
eparate reports where atorvastatin, pravastatin, and rosuv-
statin administration were shown to prevent both endo-
helial dysfunction and nitrate tolerance in the arterial
irculation of normocholesterolemic rats (9–11), at least in
art, by preventing GTN-associated oxidative stress.
Findings from the current study suggest that atorvastatin
revents the development of nitrate tolerance in humans.
n visit 1, standing blood pressure values were significantly
ower than baseline values after 3 h in those who received
Figure 3 FBF Responses to ACh Coinfused With Vitamin C
Bar graph showing responses to incremental intra-arterial infusions of ACh
(7.5, 15, and 30 g/min) coinfused with vitamin C (VitC) in the 3 groups. The
FBF is expressed as the ratio of infused to noninfused arm. The ACh
responses were normalized in the GTN plus placebo group when coinfused with
vitamin C (p  NS, for the effect of group). The ACh responses were signifi-
cantly different when coinfused with vitamin C than during normal saline coinfu-
sion (p  0.01, for the interaction of time and group). Data are mean  SEM.
Statistical analysis was performed after natural log transformation. Abbrevia-
tions as in Figure 2.
GTN  Atorvastatin Atorvastatin
1.0 0.2 (0.0 0.1) 1.0 0.3 (–0.1 0.3)
3.5 2.1 (1.1 0.6) 2.9 1.1 (1.0 0.3)
4.6 2.5 (1.4 0.6) 4.1 2.0 (1.3 0.4)
5.3 2.8 (1.5 0.5) 5.1 2.1 (1.6 0.4)
1.0 0.2 (0.0 0.2) 1.0 0.3 (0.0 0.3)
2.8 1.3 (0.9 0.5) 3.1 0.7 (1.1 0.2)
4.2 2.6 (1.2 0.7) 3.2 1.4 (1.1 0.4)
4.8 2.7 (1.4 0.5) 4.9 2.5 (1.5 0.5)
presented as mean SD (mean ln SD ln). *p 0.01, for the effect
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December 28, 2010/January 4, 2011:93–8 Nitroglycerin and Endothelial FunctionTN. In contrast to the GTN plus placebo group, where
lood pressure values returned to baseline after 7 days of
ontinuous therapy, those in the GTN plus atorvastatin
roup had values that remained significantly lower than
aseline, indicating a sustained vasodilatory effect of GTN.
n addition, blood pressure responses to sublingual GTN
ere blunted significantly in the GTN plus placebo group
fter 7 days of transdermal GTN therapy, an effect that was
revented by the coadministration of atorvastatin. These
esults are in agreement with the previously mentioned
nimal studies documenting a prevention of GTN tolerance
hrough coadministration of an HMG-CoA reductase in-
ibitor (9–11).
Our results are in agreement with prior reports in animal
odels that atorvastatin prevents the development of endo-
helial dysfunction during continuous GTN therapy in
umans. We found FBF responses to ACh in the GTN plus
torvastatin group to be significantly greater than those in
he GTN plus placebo group after 7 days of treatment. In
ontrast, we observed a significant increase in FBF re-
ponses when ACh was coinfused with vitamin C in the
TN plus placebo group, whereas there was no change in
he GTN plus atorvastatin group. Taken together, these
esults suggest that an important component of atorvasta-
in’s ability to preserve endothelial responses is via a direct or
ndirect antioxidant mechanism. As mentioned above, the
ypothesized sources of ROS in the setting of GTN-
nduced endothelial dysfunction are multiple; thus, it is
ossible that atorvastatin may exert its antioxidant effects on
ultiple targets. Previous studies have suggested that
MG-CoA reductase inhibitors may counteract the GTN-
nduced increase in ROS by directly decreasing nicotin-
mide adenine dinucleotide phosphate oxidase activity, by
reventing NOS uncoupling and preserving NOS-mediated
O production, or both (9–11). Our group has previously
emonstrated that the abnormal responses to ACh during
hronic GTN therapy are at least partly related to abnor-
alities in NOS activity (4,8). This point was emphasized
y the fact that these responses can be normalized by
harmacologically preventing NOS uncoupling (8). Simi-
arly, chronic nitrate therapy has been demonstrated to cause
n up-regulation in endothelial NOS expression, but a
ecreased NO bioavailability resulting from uncoupling of
he enzyme (22). Our observations suggest that HMG-CoA
eductase inhibitors, in this case atorvastatin, have the
nalysis of Lipid ParametersTable 3 Analysis of Lipid Parameters
Visit 1
Total Cholesterol HDL LDL T
GTN  placebo 4.0 0.7 1.5 0.4 2.1 0.6 0
GTN  atorvastatin 3.6 0.7 1.4 0.3 1.9 0.6 0
Atorvastatin 3.8 0.7 1.5 0.3 1.9 0.5 1
ata are in millimoles per liter. *p  0.0001 versus corresponding value on visit 1. †p  0.05 ve
HDL  high-density lipoprotein; LDL  low-density lipoprotein; other abbreviations as in Table 1apacity to restore NOS function via a mechanism that todifies the increased free radical response that occurs
uring sustained nitrate exposure (20). This, in turn, seems
o prevent both the development of endothelial dysfunction
nd nitrate tolerance.
In the current study, the FBF responses to ACh in the
TN plus atorvastatin group were the same as those
bserved in the atorvastatin alone group. This raises the
ossibility that the effect of atorvastatin may depend on an
ndependent potentiation of FBF responses, rather than a
rue prevention of nitrate-induced endothelial dysfunction.
wo considerations suggest that this is not the case. First,
he ACh-induced FBF responses in the atorvastatin alone
roup were very similar to those previously observed in our
aboratory in healthy volunteers receiving no therapy (4),
nd previous reports consistently showed that HMG-CoA
eductase inhibitors have a marginal (if any) impact on FBF
esponses to ACh in healthy volunteers (23,24). Second, the
oadministration of vitamin C markedly improved the FBF
esponses in the GTN plus placebo group, but did not
hange the responses in the GTN plus atorvastatin group,
hich suggests that atorvastatin and vitamin C act via
imilar mechanisms (i.e., by preventing GTN-induced ox-
dative stress).
tudy limitations. We observed significant reductions in
oth total cholesterol and low-density lipoprotein levels in
ubjects who received GTN plus atorvastatin or atorvastatin
lone, and thus we cannot discount that the lipid-lowering
ffect of atorvastatin may have contributed to the preserva-
ion of vascular function with chronic GTN. However, the
bove considerations suggest that our observations do not
epend on simple potentiation of FBF responses induced by
torvastatin. We believe that these observations allow us to
xclude the lipid-lowering effect of HMG-CoA reductase
nhibitor administration as a potential explanation for our
bservations. The current study used a treatment period of
days of continuous therapy, and the impact of longer
eriods of concurrent therapy, particularly in clinical prac-
ice, warrants further investigations. Importantly, endothe-
ial dysfunction in patients with cardiovascular disease also is
rought about by risk factors for cardiovascular disease such
s age, smoking, hypertension, hyperlipidemia, and diabe-
es. For this mechanistic study, we elected to recruit normal
olunteers to avoid the confounding effects of concurrent
rug therapy that also may act to improve endothelial
unction independently. One intriguing hypothesis raised by
Visit 2
rides Total Cholesterol HDL LDL Triglycerides
0.41 4.0 0.7 1.5 0.4 2.0 0.6 0.83 0.39
0.52 2.4 0.4* 1.3 0.2 0.8 0.4* 0.58 0.24
0.84 3.0 1.2† 1.4 0.3 1.3 0.9† 0.76 0.54
rresponding value on visit 1.riglyce
.85
.86
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Nitroglycerin and Endothelial Function December 28, 2010/January 4, 2011:93–8he phenomenon of nitrate tolerance and nitrate-induced
ndothelial dysfunction involved patients not receiving
MG-CoA reductase inhibitors. It is possible that the
ntire area of nitrate tolerance will require re-exploration in
ight of the potential effects of cotreatments such as vitamin
upplements, HMG-CoA reductase inhibitors, angiotensin-
onverting enzyme inhibitors, and so forth, which are now
ommon treatment strategies in cardiovascular disease. Fur-
her studies will be needed in patients with overt athero-
clerotic disease receiving treatment regimens currently
eing used in clinical practice.
onclusions
e demonstrate the ability of atorvastatin to prevent the
evelopment of tolerance and endothelial dysfunction asso-
iated with chronic GTN therapy in healthy volunteers.
urthermore, our data suggest that an antioxidant effect of
torvastatin is at least partly responsible in the prevention of
hese GTN-induced effects. We believe that our observa-
ions emphasize the need for more clinical investigations
oncerning the impact HMG-CoA reductase inhibition on
he efficacy and the vascular impact of organic nitrates.
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